These data suggest that hepatic SIRT6 likely inhibits the development of NAFLD by inhibiting lipogenesis, lipid droplet formation, inflammation, and fibrogenesis. This evidence concerns the gene SIRT6 and metabolic dysfunction-associated steatotic liver disease.